Collectively, these findings indicate that monoclonal antibody therapies directed against HER2 and HER3 lack efficacy in metastatic prostate cancer cells, but corresponding ADCs may have therapeutic potential. This evidence concerns the gene ERBB3 and prostate carcinoma.